Palisade Bio Inc (PALI) Q1 2024 Earnings Report

Palisade Bio reported QQ1 2024 results with no revenue and a substantial operating loss, reflecting the company’s clinical-stage, pre-revenue business model. The quarter ended March 31, 2024 showed an operating loss of approximately $3.673 million and a net loss of about $3.527 million, with EBITDA of roughly -$3.525 million. R&D spending dominated the cost stack at $2.214 million, complemented by G&A of $1.460 million and modest other expenses. The lack of revenue and ongoing development spend drove a negative EBITDA and net income, while the company maintained a solid liquidity position with cash and equivalents around $11.276 million and a net cash position (net debt) of roughly -$11.093 million. Cash burn for the quarter was $3.18 million from operations, and financing activities contributed about $2.024 million, resulting in a net cash decrease of $1.156 million for the quarter and ending cash of $11.302 million. Management commentary specific to QQ1 2024 is not included in the supplied transcript data; as a result, quotes from the earnings call are not available in this dataset. Given the pre-revenue status, Palisade’s near-term investment thesis hinges on successful execution of LB1148 development, potential strategic partnerships, and the ability to secure subsequent funding to sustain ongoing R&D and operating activities. Investors should monitor the company’s ability to secure additional financing, progress in LB1148, and any updates to the clinical program timeline and any potential collaboration or licensing discussions.